+1 206 452 8753 serickson@cooley.com
Sonya Erickson is a member of the firm's board of directors. She has over 30 years of experience counseling emerging growth companies, established technology businesses and venture capital funds. Her clients range from early stage startups to larger public companies.
Download full bio
Lattice’s Valuation Climbs to $1 Billion With Series E Round
Rodeo Therapeutics Agrees to Sell to Amgen for $721 Million
Lodo Therapeutics Enters $970 Million Multi-Target Collaboration With Genentech
Alder Biopharmaceuticals $80 Million Initial Public Offering
Bolt Biotherapeutics – $264.5 Million IPO
Emerging Companies
Mergers & Acquisitions
Public Companies
Venture Capital
Life Sciences
Medtech
Technology
University of Washington School of LawJD, 1990
Pepperdine UniversityBS, Business and EconomicsWith honors, 1987
California
Washington
Q1 2021 Venture Financing Report – A Strong Start to the Year May 6, 2021
Lattice’s Valuation Climbs to $1 Billion With Series E Round April 8, 2021
Q4 2020 Venture Financing Report – A Record Close to a Turbulent Year February 19, 2021
View all
Washington State Bar Association
Chambers USA: Corporate/Commercial
The Best Lawyers in America, Venture Capital Law (2004 - 2019)
Chambers USA: America's Leading Lawyers for Business (2013 - 2015)
Washington Super Lawyers (2014 - 2016)
+1 206 452 8753 office +1 206 452 8800 fax serickson@cooley.com
1700 Seventh AvenueSuite 1900Seattle, WA 98101-1355